This contract involves the supply of the drug Durvalumab, which is detailed in Annex 1a of the procurement documentation. The National Institute of Oncology, Maria Skłodowska-Curie National Research Institute, located in Krakow, Poland, is seeking suppliers to provide this pharmaceutical product. Th
Tender closed on 8 Dec 2025. Awaiting award.
No single supplier dominates the field.
In healthcare medical, NATIONAL INSTITUTE OF ONCOLOGY NAMED AFTER MARIE SKODOWSKACURIE NATIONAL RESEARCH INSTITUTE BRANCH IN KRAKOW has awarded 3 contracts to 3 suppliers.
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract involves the supply of the pharmaceutical drug Eribulinum. The National Institute of Oncology, Maria Skłodowska-Curie National Research Institute, located in Krakow, Poland, is seeking suppliers to provide this medication. The deadline for submitting proposals is March 13, 2026. For mo
This contract involves the supply of servers and licenses for Windows Server Datacenter 2025. Detailed specifications can be found in attachments 1, 1a, and 1b of the procurement documentation. The total value of the contract is €371,250. The buyer is the National Institute of Oncology, Maria Skłodo
This contract involves the supply of a PET/CT scanner and a SPECT scanner, along with necessary room adaptations. The project is part of the modernization and enhancement of the National Cancer Institute in Krakow, aimed at improving the quality and range of services offered to patients within the N
This contract involves the renovation and modernization of selected rooms in the Clinic Building located at Garncarska Street 15/17, 31-115 Kraków, plot number 75, district 62, Śródmieście. Detailed information can be found in the attached documents: Attachment 11 (project documentation), Attachment
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
GHFT seeks echocardiography service providers to reduce diagnostic waiting times through a two-year contract with optional extensions starting April 2027.
St Helens Council is soft market testing for providers to deliver the Healthy Child Programme (health visiting and school nursing for ages 0-19), with an anticipated annual value of £4.2m over 5 years plus optional extensions.
